Aprilbio Co. Ltd. (397030.KQ) stock: key figures, P/E, revenue and dividend
Energy · Coal & Consumable Fuels · South Korea
Aprilbio Co. Ltd. financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 27.51 bn KRW | 2.17 bn KRW |
| Gross profit | 27.51 bn KRW | 2.17 bn KRW |
| Operating income | 16.75 bn KRW | -7.26 bn KRW |
| EBIT | 21.43 bn KRW | -9.11 bn KRW |
| Net income | 20.01 bn KRW | -9.73 bn KRW |
| Diluted EPS – continuing operations | 891.67 KRW | -419.16 KRW |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Aprilbio Co. Ltd.
AprilBio Co.,Ltd. develops long-acting type biobetter and antibody biologics. The company develops antibody drugs, double antibodies, long-acting antibody drugs, long-acting protein drugs, and ADC-applied antibodies. It is developing various products for use in the treatment of rare diseases, cancer, male infertility, autoimmune and inflammatory diseases. The company was founded in 2013 and is headquartered in Chuncheon-si, South Korea.
More stocks
- Coincheck Group N.V. Ordinary Shares (CNCK)
- Critical Holdings Berhad (0291.KL)
- Citizens Bancorp Investment Inc (CBTN)
- Dimerco Data System (5403.TWO)
- CviLux Corp (8103.TW)
- Mega Fortris Berhad (5327.KL)
- WS WESPORTS GROUP (WSG.ST)
- CONDUENT Inc (CNDT)
- Enli Technology Co.,Ltd (7728.TWO)
- Skinkandy Limited (SK1.AX)
- Northern Ocean Ltd (NOL.OL)
- 104 Corporation (3130.TW)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.